The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells
Open accessAbstract
The immunosuppressive drug cyclosporin A (CsA) has considerable nephrotoxic side effects which seem to be related to its interference with the synthesis of vasoactive prostanoids. Therefore, the molecular mechanism of the effect of CsA on the synthesis of prostaglandin E2 (PGE2) was investigated in rat renal mesangial cells (RMC). CsA effectively inhibited the PGE2 synthesis induced by inflammatory cytokines such as interleukin 1 (IL-1) or tumor necrosis alpha (TNF alpha). The induction by IL-1 and the inhibition by CsA were reflected in the enzyme activity of the cyclooxygenase. The changes in activity could be correlated with the expression of the inducible cyclooxygenase isoform (COX2), which is characterized by its 4.4 kb mRNA: the expression of this enzyme was enhanced by IL-1 and suppressed by CsA on the mRNA and protein level as determined by Northern and Western blot analyses. Suppression of COX2 mRNA was also observed when the message was induced by LPS or ionophore A23187. The expression of the basal cyclooxygenase isoform (COX1), which was constitutively expressed in proliferating mesangial cells, was not affected by IL-1 or CsA. Interferon gamma, which did not induce prostaglandin synthesis or influence COX mRNA expression, augmented the expression of MHC antigens in RMC. This induction was insensitive to CsA treatment. We could thus show that the inducible cyclooxygenase isoform in mesangial cells is a molecular target for CsA providing a possible mechanism for t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies involving angiotensin-I-converting enzyme inhibitors have demonstrated beneficial effects on proteinuria but have not demonstrated the superiority of blockade of the renin-angiotensin system in slowing the progression to end-stage renal disease over nonblockade forms of therapy. 14-20”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [15]
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1006/abio.1987.9999 · Cited by 65,515
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.
O’Banion, M. K., Winn, V. D., & Young, D. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4888 · Cited by 812
Prostanoid biosynthesis and mechanisms of action
Smith, W. L. (1992) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1992.263.2.f181 · Cited by 551
The long-term course of cyclosporine-associated chronic nephropathy
Myers, B. D., Sibley, R. K., Newton, L., Tomlanovich, S. J., Boshkos, C., Stinson, E. B., Luetscher, J. A., Whitney, D. J., Krasny, D., Coplon, N. S., et al. (1988) · Kidney International · doi:10.1038/ki.1988.38 · Cited by 504
Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells.
Maier, J. A. M., Hla, T., & Maciag, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38515-1 · Cited by 479
The glomerular mesangial cell: an expanding role for a specialized pericyte
Schlöndorff, D. (1987) · The FASEB Journal · doi:10.1096/fasebj.1.4.3308611 · Cited by 438
Myers, P. D. B. D. (1986) · Kidney International · doi:10.1038/ki.1986.280 · Cited by 331
English, J., Evan, A. P., Houghton, D. C., & Bennett, W. M. (1987) · Transplantation · doi:10.1097/00007890-198707000-00027 · Cited by 298
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–178 of 178
Progressive renal and cardiovascular disease: Optimal treatment strategies
Weir, M. R. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00591.x · Cited by 17
Evidence‐based treatment of hypertension in patients with diabetes mellitus
Onuigbo, M. A. C., & Weir, M. R. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00222.x · Cited by 16
Diabetic Hypertensive Patients: Improving Their Prognosis
Makrilakis, K., & Bakris, G. L. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199800002-00006 · Cited by 17
Schaefers, H.-J., & Goppelt‐Struebe, M. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00503-5 · Cited by 17
Self-citationAntihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria
Cooper, M. E., McNally, P. G., & Boner, G. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4499-9_35 · Cited by 17
Hoffmann, U., Banas, B., Krüger, B., Pietrzyk, M. C., Obed, A., Segerer, S., Kammerl, M., Rümmele, P., Riegger, G. A. J., & Krämer, B. K. (2006) · Transplant International · doi:10.1111/j.1432-2277.2005.00261.x · Cited by 16
Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus
Joven, M. H., & Anderson, R. J. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0613-6 · Cited by 15
Proteinuria and Clinical Outcomes in Hypertensive Patients
Maione, A., Annemans, L., & Strippoli, G. F. (2009) · American Journal of Hypertension · doi:10.1038/ajh.2009.161 · Cited by 14
Sica, D. A., & Elliott, W. J. (2001) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2001.00678.x · Cited by 14
Prognosis of diabetic nephropathy: how to improve the outcome
Remuzzi, G., & Ruggenenti, P. L. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(98)00016-3 · Cited by 13
Swales, P., & Williams, B. (2002) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2002.022 · Cited by 12
Epstein, M., & Tobe, S. W. (2001) · Current Hypertension Reports · doi:10.1007/s11906-001-0061-3 · Cited by 12
Scholz‐Pedretti, K., Eberhardt, W., Rupprecht, G., Beck, K., Spitzer, S., Pfeilschifter, J. M., & Kaszkin, M. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703419 · Cited by 12
Primary and secondary prevention of chronic kidney disease
Zandi‐Nejad, K., & Brenner, B. M. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000183635.00606.5b · Cited by 12
Rao, R. P., Jain, A. K., & Srinivasan, B. (2011) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320310392097 · Cited by 11
Goppelt‐Struebe, M., Esslinger, B., & Kunzendorf, U. (2003) · Clinical Transplantation · doi:10.1034/j.1399-0012.2003.02053.x · Cited by 11
Self-citationHausknecht, B., Voelkl, S., Riess, R. H., Gauer, S., & Goppelt‐Struebe, M. (2003) · Transplantation · doi:10.1097/01.tp.0000069235.95557.93 · Cited by 11
Self-citationPalmer, A. J., Valentine, W. J., & Ray, J. A. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01343.x · Cited by 11
Hypertension and Diabetes: the Scope of the Problem
Parving, H. (2001) · Blood Pressure · doi:10.1080/080370501750275866 · Cited by 10
Losartan: lessons learned from the RENAAL study
Shahinfar, S., Lyle, P. A., Zhang, Z., Keane, W. F., & Brenner, B. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.5.623 · Cited by 9
Palmer, A. J., Valentine, W. J., Ray, J. A., Roze, S., & Muszbek, N. (2007) · The European Journal of Health Economics · doi:10.1007/s10198-006-0033-2 · Cited by 9
A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient
Shammas, N. W., Sica, D. A., & Toth, P. P. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256572 · Cited by 8
Tabur, S., Oğuz, E., Sabuncu, T., Korkmaz, H., & Çelık, H. (2014) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2014.933964 · Cited by 7
Parvanova, A. I., Chiurchiu, C. R., Ruggenenti, P. L., & Remuzzi, G. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.11.1931 · Cited by 7
Tsutsumi, E., Takeuchi, K., Abe, T., Takahashi, N., KATO, T., Taniyama, Y., Ikeda, Y., Ito, S., & Abe, K. (1997) · Prostaglandins · doi:10.1016/s0090-6980(97)00059-2 · Cited by 7
Hsueh, W. A. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00141-8 · Cited by 7
Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes
Komers, R., & Komersova, K. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.11.2601 · Cited by 7
Diabetes Mellitus and Hypertension, Emerging Therapeutic Perspectives
Sowers, J. R., & Epstein, M. (1995) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.1995.tb00303.x · Cited by 7
Combination Therapy for Hypertension and Renal Disease in Diabetics as Compared to Non-Diabetics
Bakris, G. L. (1996) · Springer eBooks · doi:10.1007/978-1-4757-6749-0_55 · Cited by 7
Overview of COX-2 in inflammation: from the biology to the clinic
Pairet, M., van Ryn, J., & Distel, M. (1999) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8747-2_1 · Cited by 6
Khaja, K. A. J. A., & Sequeira, R. P. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1161 · Cited by 6
Alicic, R. Z., & Tuttle, K. R. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0073-8 · Cited by 6
Nagao, T., Nagamatsu, T., & Suzuki, Y. (1995) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.68.137 · Cited by 6
Sica, D. A. (2002) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2002.020 · Cited by 6
Proinflammatory cytokines enhance COX-1 gene expression in cultured rat glomerular mesangial cells
Tsai, C., Yu, C., Wu, T.-H., Hsieh, S., & Tsai, Y.-Y. (2003) · International Immunopharmacology · doi:10.1016/j.intimp.2003.10.003 · Cited by 6
Targeting interleukin-1 signaling for renoprotection
Bogdanova, D. A., Samsonov, M. Y., Lebedeva, S. A., Bukhanova, D., Materenchuk, M. Y., & Mutig, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1591197 · Cited by 5
Elevated levels of cyclooxygenase 1 and 2 in human cyclosporine induced gingival overgrowth
Rao, S. R., Balaji, T. M., Prakash, P. S. G., & Lavu, V. (2014) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2014.07.003 · Cited by 5
Antihypertensive drugs and the kidney
Nadim, M. K., Dua, R., & Campese, V. M. (2004) · Current Cardiology Reports · doi:10.1007/s11886-004-0046-3 · Cited by 5
Waeber, B., Weidmann, P. U., Wohler, D., & LeBloch, Y. (1996) · American Journal of Hypertension · doi:10.1016/s0895-7061(96)00055-6 · Cited by 5
Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
Ruilope, L. M., Segura, J., & Schiffrin, E. L. (2003) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2003.016 · Cited by 5
Cyclosporine nephropathy: clinical, histological, and functional aspects
de Mattos, A. M., Andoh, T. F., & Bennett, W. M. (1996) · Transplantation Reviews · doi:10.1016/s0955-470x(96)80009-7 · Cited by 5
Combination Therapy for Hypertension and Renal Disease in Diabetes
Odama, U. O., & Bakris, G. L. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4499-9_42 · Cited by 5
Machiguchi, T., Tei, M., Ono, T., & Kambara, H. (2002) · Clinical and Experimental Nephrology · doi:10.1007/s101570200029 · Cited by 4
Antihypertensive Treatment in NIDDM, With Special Reference to Abnormal Albuminuria
Cooper, M. E., & McNally, P. G. (1998) · Springer eBooks · doi:10.1007/978-1-4757-6752-0_42 · Cited by 4
Palmer, A. J., Annemans, L., Roze, S., Lamotte, M., Berto, P., Ravera, M., & Rodby, R. A. (2005) · PharmacoEconomics Italian Research Articles · doi:10.1007/bf03320534 · Cited by 3
Diabetic Nephropathy in Patients with Type II Diabetes
Lewis, J. B. (2000) · Springer eBooks · doi:10.1007/978-94-011-4088-1_9 · Cited by 3
Choices and goals in the treatment of the diabetic hypertensive patient
Basta, E., & Bakris, G. L. (2001) · Current Hypertension Reports · doi:10.1007/s11906-001-0055-1 · Cited by 3
Novel Therapies of Diabetic Nephropathy
Kaur, H., & Prabhakar, S. S. (2011) · Nephrology Research & Reviews · doi:10.4081/nr.2011.e4 · Cited by 3
Anaesthetic and Perioperative Management for Liver Transplantation
Siniscalchi, A., Pierucci, E., & Faenza, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-16997-2_9 · Cited by 2
Case-Based Study: From Prediabetes to Complications—Opportunities for Prevention
Rappaport, J. M., & Fonseca, V. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020040 · Cited by 2
Treatment of elevated blood pressure in diabetic patients
Weidmann, P. U., Teuscher, A. U., & Böhlen, L. (1997) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(96)00093-1 · Cited by 2
The treatment of patients with advanced renal involvement
van Dijk, D. (2003) · CRC Press eBooks · doi:10.3109/9780203502976-18 · Cited by 2
Microalbuminuria in Type II Diabetes
Murray, J. E. (1996) · Endocrine Practice · doi:10.4158/ep.2.3.211 · Cited by 1
Nephropathy in NIDDM Patients, Predictors of Outcome
Ruggenenti, P. L., & Remuzzi, G. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4499-9_20 · Cited by 1
de Hornedo, J. P., Fernández, M., de Arriba, G., Fernández, P. D. R., Cid, T. P., & Martínez, S. B. (2006) · Cytometry Part A · doi:10.1002/cyto.a.20230 · Cited by 1
Treating Hypertension in Patients with Diabetes
Reynolds, H. Q., & DEEDWANIA, P. C. (2002) · The Nurse Practitioner · doi:10.1097/00006205-200207000-00003 · Cited by 1
Lessons from trials in hypertensive type 2 diabetic patients
Ruilope, L. M. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0041-x · Cited by 1
Antihypertensive Therapie bei Diabetes mellitus
Wenzel, U. O., Thaiss, F., & Stahl, R. A. K. (2001) · Springer eBooks · doi:10.1007/978-3-642-59539-4_13 · Cited by 1
Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria
Cooper, M. E., & McNally, P. G. (1996) · Springer eBooks · doi:10.1007/978-1-4757-6749-0_38 · Cited by 1
Völzke, A. (2013) · Technischen Universität Darmstadt · doi:10.26083/tuprints-00003518
High blood pressure and renal disease: an overview
Strain, W. D. (2009) · Journal of Renal Nursing · doi:10.12968/jorn.2009.1.4.45314
Antihypertensive drugs and diabetic nephropathy
Mehler, P. S., & Schrier, R. W. (1999) · Current Hypertension Reports · doi:10.1007/s11906-999-0015-8
Renal protective capacity of the angiotensin receptor antagonists
Smith, R. D., & Ferrario, C. M. (2004) · Therapy · doi:10.1586/14750708.1.2.331
Campopiano, J. C. (2010) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2010.tde-11082010-142224
PPAR-γ Ligands and Diabetic Nephropathy
Isshiki, K., Koya, D., & Haneda, M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-153-6_16
Mathematisch-naturwissenschaftlichen Fakultät, I. (2005)
Schiffrin, E. L. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200203000-00007
ACE Inhibitors and Angiotensin Receptor Blockers in Kidney Disease
Weir, M. A. (2003) · CRC Press eBooks · doi:10.3109/9780203505595-10
Goppelt‐Strübe, M., & Fauler, J. (1999) · doi:10.1002/9783527613625.ch7
Combination Therapy for Hypertension and Renal Disease in Diabetes
Villarosa, I. P., & Bakris, G. L. (1998) · Springer eBooks · doi:10.1007/978-1-4757-6752-0_52
Bhargava, M. (2011) · eScholarship (California Digital Library)
Alsalemi, N., Sadowski, C. A., Elftouh, N., Louis, M., Kilpatrick, K., Houle, S. K. D., & Lafrance, J. (2022) · Figshare · doi:10.6084/m9.figshare.19681822
Alsalemi, N., Sadowski, C. A., Elftouh, N., Louis, M., Kilpatrick, K., Houle, S. K. D., & Lafrance, J. (2022) · Figshare · doi:10.6084/m9.figshare.19681828
Alsalemi, N., Sadowski, C. A., Elftouh, N., Louis, M., Kilpatrick, K., Houle, S. K. D., & Lafrance, J. (2022) · Figshare · doi:10.6084/m9.figshare.19681825
Matsuzawa, Y. (1997) · doi:10.1002/(sici)1099-0895(199703)13:1
Metadata
- Authors
- Martin, M., Neumann, D., Hoff, T., Resch, K., DeWitt, D. L., & Goppelt-Struebe, M.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Martin, Michael
- ORCID
- Neumann, Detlef
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 1994-01
- Volume
- 45
- Issue
- 1
- Pages
- 150-158
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W1965476867
- Cited by
- 178
- References
- 42
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 4 · 2020: 1 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Kidney International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- cyclosporine, cyclooxygenase-2, interleukin-1, renal mesangial cells, prostaglandin E2 synthesis, cyclooxygenase-1, TNF-α, interferon-gamma, MHC antigen expression, cyclosporine nephrotoxicity, inflammatory cytokines
- MeSH terms
- Animals, Histocompatibility Antigens Class II, Cells, Cultured, Glomerular Mesangium, Interleukin-1, Male, Prostaglandin-Endoperoxide Synthases, Recombinant Proteins, RNA, Messenger, Dinoprostone, Histocompatibility Antigens Class I, Cytokines, Cyclosporine, Cyclooxygenase Inhibitors, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review